| Vaccine |
Recommendation |
| Cholera |
No longer available in U.S. |
| Japanese encephalitis |
Full duration of protection unknown. Neutralizing antibodies may persist at least 2 years after primary immunisation |
| Hepatitis A (HAV) |
Booster not recommended for adults and children who complete primary series (2 doses) |
| Hepatitis B (HBV) |
Booster doses of vaccine are not recommended for adults and children who completed primary series according to routine schedule.1 Booster is recommended at least 6 months after the start of the accelerated schedule. |
| Influenza |
1 annual dose |
| Measles, Mumps, Rubella (MMR) |
1 dose if measles, mumps, or rubella vaccination history is unreliable and person did not have these illnesses; 2 doses for persons with occupational or other indications |
Meningococcal
Quadrivalent A,C, Y, W-135 |
Full duration of protection is unknown; immunity may persist at least 3 years in adults |
| Pneumoccocal (polysaccharide) |
One-time revaccination 5 years after original dose for persons > 65 years of age or who have immunosuppressive conditions. |
| Polio (IPV) |
For adults who have completed primary series, a single lifetime booster |
Rabies
Preexposure vaccine |
No serologic testing or boosters recommended for travellers. For persons in higher risk groups, such as rabies laboratory workers, serologic testing and booster doses are recommended. See Table 4–15. |
| Tetanus/diphtheria (Td) |
Booster every 10 years |
| Typhoid Oral |
Booster every 5 years |
| Typhoid IM |
Booster every 2 years |
| Varicella |
Booster not recommended after completion of primary series. |
| Yellow fever |
Booster every 10 years. Note that there are age-related risks for severe adverse reactions. |